Worldwide: Healthcare

A mother shares the heartbreaking story of her 22-year-old daughter's death from ketamine addiction, revealing how recreational drug use spiraled into a debilitating condition called ketamine bladder that caused chronic pain and ultimately led to fatal complications. The case exposes critical gaps in healthcare support for ketamine addiction and raises urgent questions about education, treatment pathways, and the accessibility of this Class B substance.

The phrase "clinically proven" is one of the most powerful claims in a beauty marketer's ‘Arsenal’*. It sounds scientific, authoritative, and reassuring. But in a ruling published in April 2026,...

Launching a product while a patent dispute remains unresolved has never been risk‑free, but many companies have taken the view that the commercial upside justified it.

This report examines critical commercial, legal and regulatory challenges facing life sciences and healthcare companies globally, from shareholder activism and AI-powered drug...

Welcome to the latest installment of Arnold & Porter’s Virtual and Digital Health Digest. This digest covers key virtual and digital health regulatory and public policy developments...

Global Asbestos Awareness Week has just finished – a reminder that this problem still requires action within the construction industry.

January 2026 saw significant activity as UK and EU authorities advanced major initiatives affecting the use of AI, digital technologies, data governance, and cybersecurity in healthcare and life sciences.

This article analyses the recent Court of Appeal decision in Salts Healthcare Ltd v Pelican Healthcare Ltd [2026] EWCA Civ 93, which addresses several important issues in patent law.

In April 2025, the UK Parliament and Northern Ireland Assembly approved several changes to the Medicines for Human Use (Clinical Trials) Regulations (the CTR), the law governing the regulation of clinical trials involving IMPs in the UK. These changes (the CTR Amendment) will go into effect on April 28, 2026, and will apply across England, Wales, Scotland, and Northern Ireland. The CTR Amendment is part of the UK's national strategy to promote the UK life sciences sector and streamline its regulatory...